Stockholm exchange. Sector: Healthcare. Industry: Drug Manufacturers—Specialty & Generic. Location Sweden, Stockholm.

Karo Pharma AB (publ) [KARO.STSweden

60.3USD0.1 (+0.17%)

• At close Thu Oct 06 2022

1,293,354,642 USD
MARKET CAP
278.440
PE
0.108
BETA (5y)
0.218
EPS

profit

175%

for 5 years

profit

62%

for 3 years

profit

39%

for 2 years

profit

26%

for 1 year

profit

1%

for this year

About Karo Pharma AB (publ)

Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. It offers skin health products under the Remescar, Locobase, Decubal, and indy beauty brand names; intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brand names; and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. The company also provides pain, cough, and cold products under the Paracet, Ibux, Mollipect, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Lithionit brands; and wellness products under the nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare brands. It sells its products in approximately 90 countries with Europe and the Nordic region markets through direct sales organizations and a network of distributors, as well as online. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was incorporated in 1987 and is headquartered in Stockholm, Sweden.

Karo Pharma offers a portfolio of everyday healthcare products and services that help prevent illness and treat health problems.

Karo Pharma AB (publ)
https://www.karopharma.com
© 2022 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.